The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move that strengthens the company's position in the growing immunology market, the European Commission approved SKYRIZI for treating children and adolescents aged 6 and older with moderate to severe plaque psoriasis. This decision was based on results from the pivotal Phase 3 OptIMMize-1 and OptIMMize-2 trials, which demonstrated the drug's efficacy in younger populations. The approval also included a new weight-based dosing syringe, addressing a significant medical need as one-third of psoriasis cases begin before the age of 18.
This expansion comes amid intensifying competition in the immuno-dermatology sector, where AbbVie competes with majors like Novartis (Cosentyx) and Johnson & Johnson (Tremfya). Per market data, companies are aggressively expanding indications to offset revenue declines in legacy drugs; SKYRIZI has delivered robust global sales growth exceeding 40% in recent quarters according to previous earnings reports, making it a primary growth driver as Humira sales face biosimilar pressure.
Sign in to access this content
Sign InRegarding market performance, ABBV closed at $216.63 (as of June 18, 2026), with a daily trading range between $215.37 and $222.30. Investors should monitor the impact of this operational expansion on healthcare sector margins, especially as markets digest key Eurozone data, where recent Economic Sentiment figures (June 16, 2026) showed a marked improvement at 9.5 points, significantly beating negative forecasts.